11 – 20 of 50
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia
(
- Contribution to journal › Article
-
Mark
Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma : a study of younger patients from the MCL2 and MCL3 clinical trials
(
- Contribution to journal › Article
-
Mark
Single base substitution and insertion/deletion mutational signatures in adult core binding factor acute myeloid leukemia
2022) In Leukemia(
- Contribution to journal › Letter
- 2021
-
Mark
Hairy cell leukemia and COVID-19 adaptation of treatment guidelines
(
- Contribution to journal › Scientific review
-
Mark
BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib
(
- Contribution to journal › Article
-
Mark
Single base substitution mutational signatures in pediatric acute myeloid leukemia based on whole genome sequencing
(
- Contribution to journal › Letter
-
Mark
Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma : the DSHNHL2006-1B/ACT-2 trial
(
- Contribution to journal › Article
-
Mark
HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting
(
- Contribution to journal › Article
- 2020
-
Mark
S100A6 is a critical regulator of hematopoietic stem cells.
2020) In Leukemia(
- Contribution to journal › Article